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mortality data. Study cohort was statin-naïve patients initially prescribed statin 
therapy from January 2003–July 2011, and registered within the practice for ≥1 
year preceding statin initiation. High-dose was defined as simvastatin 80mg, 
fluvastatin 80mg, atorvastatin>20mg, rosuvastatin>10mg. Adjusted Cox 
regression models were used to predict factors associated with discontinuation 
and CV event risk. RESULTS: Only 2% (4,744/218,808) of patients started on a 
high-dose statin; 4,399/4,744, (93%) on atorvastatin, a third taking atorvastatin 
80mg. Adherence was high based on prescribed medication possession ratio for 
high- (0.96, SD:0.08) and low-dose (0.95, SD:0.10) initiation. Initial dose was not a 
predictor of discontinuation in the overall population (HR:0.96 95%CI:0.91-1.02), 
but in patients with CV history, high-dose initiation was associated with lower 
discontinuation risk (HR:0.87 95%CI 0.78-0.96). In the overall population 
increased CV event rates were associated with initiation of high-dose statin 
(OR:2.07 95%CI:1.78-2.41), greater Framingham risk (OR:1.50 95%CI 1.44-1.56), 
prior unstable angina (OR:3.06 95%CI:2.53-3.71), heart failure (OR:2.73 95%CI:2.13-
3.51), and myocardial infarction (MI) (OR:4.29 95%CI:3.56-5.17). In the CV sub-
group, only prior MI was associated with increased CV event risk (OR:1.26 
95%CI:1.03-1.55). CONCLUSIONS: Initial high-dose statin was not associated with 
lower adherence or persistence; among patients with CV history, risk of 
discontinuation was significantly lower. The association of initial high-dose 
statin treatment with higher CV event rates may be due to background risk 
factors leading to use of high-dose statin.  
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OBJECTIVES: Many new catheter ablation (CA) methods based on pulmonary 
vein isolation (PVI) have been developed. The aim of this study was to assess the 
benefits and harms of additional linear ablation with PVI/ circumferential 
pulmonary vein ablation (CPVA) in comparison with PVI/CPVA in patients with 
AF. METHODS: Ovid-Medline, Ovid-EMBASE, Cochrane library, and seven Korean 
medical databases were searched to identify studies through May, 2012. To 
assess the quality of randomized controlled trials (RCTs), the Cochrane risk of 
bias tool was used. Data were independently extracted by two reviewers using a 
standardized form. Disagreements between reviewers were resolved by 
discussion and consensus. The dichotomous data were presented as pooled 
relative risk (RR) with 95% confidence intervals (CI) using random-effects model. 
RESULTS: A total of 12 RCTs (1,226 patients) were included and of poor quality. 
Differences between groups of all-cause mortality were not reported in 12 RCTs. 
PVI/CPVA plus additional linear ablation, in comparison with PVI/CPVA, 
increased freedom from atrial tachycardia (AT)/AF (RR 1.10, 95% CI 0.97-1.25, 
I2=64%) in 12 RCTs, but there was insignificant and moderate heterogeneity 
among trials. The RR of stroke, transient ischemic attack (TIA) or thrombo-
embolic events between both groups was 0.75 (95% CI 0.20-2.81, I2=0%). Fewer 
complications and adverse events were reported in the trials and there were no 
differences. CONCLUSIONS: The results of meta-analysis showed a trend of favor 
of PVI/CPVA plus additional linear ablation for freedom from AT/AF, and similar 
result in the rates of stroke, TIA or thrombo-embolic events. There is limited 
evidence to suggest that PVI/CPVA plus additional linear ablation may be a better 
treatment option compared to PVI/CPVA in patients with AF. Well-designed, 
adequately powered, and long-term clinical trials are warranted.  
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OBJECTIVES: Statin treatment has been shown to be effective in secondary 
prevention for vascular events among patients with established cardiovascular 
diseases (CVD). However, its effectiveness of primary prevention for CVD on the 
elderly is unknown. The aim of this study was to examine whether statins are 
effective in reducing CVD risk among the elderly without medical history of CVD. 
METHODS: We used population-based National Health Insurance Database to 
conduct a retrospective cohort study. We identified 5374 lipid-lowering drugs 
users aged over 55 years old who were first-time users of statin or lowering 
cholesterol medications for primary prevention purpose between year 2000 and 
2003. We used cox proportional hazard model to analyze the risk of coronary 
artery heart disease, cerebrovascular disease or peripheral arterial occlusion 
disease during follow-up time. Interaction terms of age and statins were 
included in the model to examine the heterogeneous effect of statins across age 
groups. We used propensity score to adjust the potential self-selection effect of 
using statins on CVD risks. RESULTS: During the 6-10-year follow-up period, 2944 
patients experienced new-onset CVD. The statins users had lower risk for CVD 
events compared to non-statin lipid-lowering drug users (adjusted hazard ratio 
0.86; 95% CI, 0.78-0.93; P=.0005). The age/statin interaction term was not 
statistically significant (P=.5562). CONCLUSIONS: Statin therapy was effective in 
preventing new onset of CVD among the elderly patients.  
 
PCV17  
ATTAINMENT OF LDL-CHOLESTEROL GOALS IS SUBOPTIMAL WITH 
ROSUVASTATIN MONOTHERAPY IN US PATIENTS AT HIGH CARDIOVASCULAR 
RISK  
Marrett E, Zhang Q, Zhao C, Ramey D, Neff DR, Tershakovec AM 
Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA  
OBJECTIVES: Statins are the first recommended pharmacotherapy to lower LDL-
C, with rosuvastatin as the most potent available statin. Clinical outcomes are 
improved with statin use in patients at high risk for cardiovascular disease 
(CVD). Guidelines recommend specific LDL-C goals for patients dependent on 
pre-existing CV risk factors. The present analysis examined LDL-C goal 
attainment in US patients at high CV risk treated with rosuvastatin 
monotherapy. METHODS: In a retrospective study using the GE Healthcare 
Centricity database, patients who received a prescription (Rx) for rosuvastatin 
monotherapy (index Rx) between January 1, 2008 and December 31, 2010 were 
identified. Included were patients with coronary heart or atherosclerotic vascular 
disease, ≥1 LDL-C measurement between 3 months and 1 year post-index Rx, 
and medical records for 1 year prior to and following index Rx. Proportions of 
patients attaining LDL-C <70 and <100 mg/dL were estimated for all patients, as 
well as by rosuvastatin daily dose. RESULTS: Of 6004 patients (age=66 yrs [SD 10]; 
56% males), 15%, 39%, 29%, and 17% received Rxs for 5, 10, 20 and 40 mg 
rosuvastatin, respectively. Overall, mean follow-up LDL-C was 89 mg/dL (SD 37); 
only 32% of patients had an LDL-C <70 mg/dL and 72% had an LDL-C <100 mg/dL. 
By increasing dose, mean LDL-C decreased and proportions at goal generally 
increased. For goal of LDL-C <70 mg/dL, 39% of all patients had a follow-up LDL-C 
≥20 mg/dL above this goal, while 16% had an LDL-C ≥20 mg/dL above the 100 
mg/dL goal. CONCLUSIONS: The proportion of patients at high CV risk achieving 
recommended LDL-C goals with rosuvastatin monotherapy was suboptimal, with 
more than 63% not achieving the current optional LDL-C goal of <70 mg/dL 
across doses. This suggests a treatment gap and more effective lipid-lowering 
strategies, such as aggressive dose titration or additional therapies, are 
warranted in this high-risk population.  
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OBJECTIVES: Despite evidence from randomized controlled trials which show 
that treatment with high-intensity statins can result in an additional 16% 
reduction in CVD events compared to moderate-dose statins, only 20-25% of very 
high risk patients receive high-intensity statins. Geographic variation in statin 
prescribing, in addition to the existence of a “treatment risk paradox” in which 
complex patients with apparently more to gain from treatment are less likely 
treated, may be associated with this low rate. Our objective is to determine 
whether there is an association between patient complexity and the intensity of 
statin treatment following acute myocardial infarction (AMI) by geographical 
region. METHODS: This was a retrospective cohort study of 124,397 Medicare 
patients with fee-for service Part A and B, and the Part D benefit who were 
hospitalized with AMI in 2008 or 2009. Patient complexity was defined by the 
presence or absence of diabetes, heart failure, and chronic kidney disease in the 
year prior to admission. Treatment with atorvastatin 40,80mg; and rosuvastatin 
20,40mg in the first thirty days post discharge was defined as high-intensity; 
other statin treatment as low/moderate intensity, and the absence of a fill as no 
treatment. Area treatment rates (ATRs) adjusted for baseline patient 
characteristics were calculated and grouped into quintiles of “no treatment”, 
“low/moderate”, and “high” treatment areas. Tables were generated calculating 
statin intensity treatment rates by comorbidity-based AMI patient complexity. 
RESULTS: Those patients with no evidence of any complex conditions have the 
lowest "no treatment" rates (36.4%), while the highest "no treatment" rates occur 
among those with all three conditions (54.2%). Substantial geographic variation 
in the intensity of statin treatment within patient complexity subgroups is 
revealed using the ATR method. CONCLUSIONS: Despite guidelines promoting 
the use of high-intensity statins, more complex patients are less likely to be 
treated and treatment discretion is revealed in the geographic variation.  
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OBJECTIVES: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have 
shown safety and efficacy for treatment of AF. The objective of this study was to 
conduct meta-analysis and present evidence for safety of Dabigatran versus 
Warfarin for treatment of AF. METHODS: For this meta-analysis we included 
randomized controlled trials (RCTs) evaluating Dabigatran for the treatment of 
AF. We included studies that were: 1) a RCT in humans; 2) an investigation of 
patients with nonvalvular atrial fibrillation; 3) an evaluation of dabigatran 
compared with warfarin or each other; and 4) a report of results of stroke or 
systemic emboli and major bleeding. A systematic literature search for 
dabigatran trials was undertaken for the databases Pubmed, Embase, Biosis, 
Google Scholar, and Cochrane. Data was collected for the study size, 
interventions, year and total bleeding events. For meta-analysis, random effects 
and fixed effects models were used to obtain cumulative statistics. RESULTS: 
Two RCTs with a total of 12,268 patients were identified. The pooled event rate 
for Dabigatran for total bleeding events was 31.9% (95% CI 31%-33%). The pooled 
response rate for Warfarin for total bleeding events was 35.1% (95% CI 34%-37%). 
The cumulative relative risk for total bleeding events with Dabigatran versus 
Warfarin was 1.1 (95% CI 1.08-1.12). CONCLUSIONS: Meta-analysis shows 
Dabigatran has a slightly lower rate of total bleeding events compared to 
Warfarin.  
